David Hutton

The Ergo-Series of the OMNI Surgical System maximizes ergonomics and surgical ease-of-use while continuing to enable surgeons to perform minimally invasive, implant-free glaucoma procedures.

According to the company, the funding supports the Phase 2 clinical study of ONL1204 ophthalmic solution to evaluate the safety and efficacy in patients diagnosed with macula-off rhegmatogenous retinal detachment.

The 2023 Harrington Prize for Innovation in Medicine recognizes Jean Bennett, MD, PhD, and Albert M. Maguire, MD, for their work in retinal gene therapy for genetic diseases.

The company’s Purely Soothing eye drop is used as an anti-inflammatory used to assist with symptoms of ocular irritation and/or swelling, including dry eye.

Under the terms of the agreement, Grifols to have worldwide exclusive commercial rights to Selagine’s treatment upon regulatory authorization, expected in early 2029.

Researchers have identified a new target to prevent the formation of abnormal tangles of blood vessels associated with eye conditions such as neovascular age-related macular degeneration, proliferative diabetic retinopathy and ischemic retinal vein occlusion.

Ophthalmologists could find themselves treating a growing number of young people who are applying lip balm to their eyelids, only to experience discomfort and vision issues when it gets into their eyes.

According to the company, post-hoc time-to-event analysis signals up to 59% risk reduction in rate of vision loss compared to sham treatment at 12 months. The analysis will be presented at the ARVO Annual Meeting from April 23-27 in New Orleans.

At the American Glaucoma Society meeting in Austin, Texas, the company presented findings demonstrating the safety and efficacy of its FLigHT treatment.

Priya M. Mathews, MD, MPH discusses ophthalmology and what she wishes she knew to start her career. As well as tips for other ophthalmologists who are just starting their careers.

When tested, the recalled Artificial Tears used by the firefighter were found to contain large amounts of Pseudomonas Aeruginosa bacterial contamination.

The regulatory milestone fulfills the company’s goal to file the IND for OCU200 within the first quarter of 2023.

David S. Boyer, MD, presented data from the PHOTON study examining the safety and efficacy of high-dose aflibercept for treatment of diabetic macular edema at the 2023 Angiogenesis, Exudation, and Degeneration conference.

Dr. Jai Parekh, a clinical associate professor of Ophthalmology/The New York Eye & Infirmary of the Mount Sinai School of Medicine and David Hutton, Managing Editor of Opthalmology Times discuss the importance of ocular health prior to cataract and refractive surgery, specifically with osmolarity testing.

The company’s iDose TR is a micro-invasive intraocular implant designed to continuously deliver therapeutic levels of a proprietary formulation of travoprost from within the eye for extended periods of time.

Researchers from Tokyo Medical and Dental University evaluated the safety of an anti-VEGF drug, aflibercept, in a cell culture model exposed to human T-cell lymphotropic virus type 1, which is known to cause a number of diseases, including inflammatory diseases of the eye.

The Cardinal Health study reveals provider perceptions of commercially available biosimilars and anticipated launches, which have the potential to increase equitable access to critical treatments.

According to Regeneron, the BLA is supported by two pivotal trials demonstrating non-inferior vision gains to aflibercept injection, with a majority of patients maintaining extended dosing regimens through 48 weeks.

Arun Singh, MD, discusses Retinoblastoma in 2023 and the advancements of tumor chemotherapy from his presentation at the Asia-Pacific Academy of Ophthalmology (APAO) 2023 conference.

According to the company, the investigational, novel eye drop candidate was assigned a PDUFA goal date of October 22, 2023.

Ophthalmologists see new therapy as having a major impact on how geographic atrophy is treated.

At the EnVision Summit Ophthalmology in Puerto Rico, Grace Sun, MD, made a presentation titled "Surgical Curriculum for Ophthalmology Residents" to train them to be competent in a broad range of basic and advanced surgical skills.

At the EnVision Summit Ophthalmology 2023 in Puerto Rico, Eva Kim, MD, made a presentation titled "ICL and Clear Lens Exchange: Choosing the Right Approach."

During the EnVision Summit Ophthalmology in Puerto Rico, Victor Villegas, MD, made a presentation titled "From a Retina Perspective: Comanagement of AMD, DME and CME in the Setting of Cataract Surgery," focusing on how to comanage patients that have macular degeneration, diabetic maculopathy and cystoid macular edema.

David Huang, MD, PhD, is recognized as a co-creator of a widely used medical imaging technology.

According to the company, the app features new content, including podcasts, discussion forums and downloadable content for eyecare professionals.

The company announced a PDUFA goal date of Aug. 19, 2023. The FDA has not identified any potential review issues and is not currently planning to hold an Advisory Committee meeting for avacincaptad pegol.

Three of Frontera’s gene therapy product candidates have entered clinical trials since the beginning of the year.

According to a news release, Akari is targeting an Investigational New Drug application submission to the FDA in the first half of 2024.

The collaboration may provide insights to help improve the treatment paradigm for retinal disorders.